Your browser does not allow JavaScript!
JavaScript is necessary for the proper functioning of this website. Please enable JavaScript or use a modern browser.
Repository of the University of Ljubljana
Open Science Slovenia
Open Science
DiKUL
slv
|
eng
Search
Advanced
New in RUL
About RUL
In numbers
Help
Sign in
Details
Improving the histologic detection of DSA-negative antibody-mediated rejection in kidney transplants
ID
Hidalgo, Luis G.
(
Author
),
ID
Arnol, Miha
(
Author
),
ID
Kojc, Nika
(
Author
),
ID
Večerić-Haler, Željka
(
Author
),
ID
Halloran, Philip F
(
Author
), et al.
PDF - Presentation file,
Download
(2,47 MB)
MD5: 945050CA962CDA9C441E173C598C5771
URL - Source URL, Visit
https://www.sciencedirect.com/science/article/pii/S1600613525029430
Image galllery
Abstract
Emerging treatments for antibody-mediated rejection (ABMR, NEJM391(2):122-132) have increased the importance of ABMR detection when donor-specific antibody (DSA) is negative. We addressed this issue in the Trifecta-Kidney study (ClinicalTrials.gov #NCT04239703) using three centralized tests in 690 kidney transplant biopsies: DSA (One Lambda Inc.), blood donor-derived cell-free DNA (dd-cfDNA, Prospera™ test, Natera, Inc.), and molecular biopsy assessment (MMDx). We used an “AutoBanff 2022” algorithm to model the impact of alternative DSA interpretations on the histologic diagnosis of “DSA-negative” ABMR following Banff guidelines, including agreement with dd-cfDNA and molecular ABMR. Lowering MFI cutoffs for DSA-positivity did not improve detection of DSA-negative ABMR. However, simply calling all DSA positive allowed Banff 2022 guidelines to identify 46% more ABMR cases with no measurable DSA, and per Net Reclassification Improvement increased agreement between histologic diagnoses and both dd-cfDNA (P=7.72E-7) and molecular ABMR (P=7.69E-7). New ABMR cases were as strongly positive for dd-cfDNA and molecular ABMR as those found using the conventional DSA interpretation. A validation set analysis using INTERCOMEX study data (ClinicalTrials.gov NCT#01299168) confirmed these findings, and found that the new DSA-negative ABMR cases identified by calling all DSA positive had the same risk for graft loss as those found with conventional DSA interpretation.
Language:
English
Keywords:
donor-derived cell-free DNA
,
kidney biopsy
,
donor-specific antibody
,
microarrays antibody-mediated rejection
,
kidney transplant rejection
Work type:
Article
Typology:
1.01 - Original Scientific Article
Organization:
MF - Faculty of Medicine
Publication status:
Published
Publication version:
Version of Record
Year:
2026
Number of pages:
Str. 117-130
Numbering:
Vol. 26, iss. 1
PID:
20.500.12556/RUL-181417
UDC:
616.61
ISSN on article:
1600-6143
DOI:
10.1016/j.ajt.2025.08.029
COBISS.SI-ID:
246735107
Publication date in RUL:
07.04.2026
Views:
336
Downloads:
211
Metadata:
Cite this work
Plain text
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Copy citation
Share:
Record is a part of a journal
Title:
American journal of transplantation
Shortened title:
Am. j. transplant.
Publisher:
Elsevier, American Society of Transplantation & American Society of Transplant Surgeons
ISSN:
1600-6143
COBISS.SI-ID:
24071897
Licences
License:
CC BY-NC-ND 4.0, Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Link:
http://creativecommons.org/licenses/by-nc-nd/4.0/
Description:
The most restrictive Creative Commons license. This only allows people to download and share the work for no commercial gain and for no other purposes.
Projects
Funder:
Natera, Inc
Acronym:
Trifecta-Kidney
Funder:
Transcriptome Sciences Inc
Acronym:
Trifecta-Kidney
Funder:
Alberta Transplant Applied Genomics Centre
Acronym:
Trifecta-Kidney
Similar documents
Similar works from RUL:
Similar works from other Slovenian collections:
Back